Comparison of gene expression profiles of lymphoma cell lines from transformed follicular lymphoma, Burkitt's lymphoma and de novo diffuse large B-cell lymphoma

被引:23
|
作者
Maesako, Y [1 ]
Uchiyama, T [1 ]
Ohno, H [1 ]
机构
[1] Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Sakyo Ku, Kyoto 6068507, Japan
关键词
D O I
10.1111/j.1349-7006.2003.tb01518.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To determine the specific gene expression in B-cell lymphoma subtypes, we compared expression profiles of cell lines from transformed follicular lymphoma (tFL), Epstein-Barr virus-negative (EBV(-)) Burkitt's lymphoma (BL) and EBV(+)BL. Complementary DNAs were synthesized from these cell lines and hybridized with the Atlas Human 1.2 Array membrane. Hierarchical clustering analysis based upon the levels of 43 genes highlighted characteristic expression patterns of the 3 lymphoma subtypes. Genes expressed at higher levels in tFL than EBV(-)BL and EBV(+)BL included calcium/calmodulin-dependent protein kinase I (CAMK1) and mitogen-activated protein kinase 10 (MAPK10). EBV(-)BL was characterized by high-level expression of amyloid beta precursor protein (APP), heat shock 27 kD protein 1 (HSPB1) and mothers against decapentaplegic homolog 1 (MADH1). Gardner-Rasheed feline sarcoma viral oncogene homolog (FGR) was the most significant gene to delineate EBV(+)BL. A subtype prediction algorithm using 34 genes correctly classified 22 (92%) of 24 lymphomas into FL/tFL, EBV(-)BL or EBV(+)BL. By comparison with normal reference B-cell materials, the expression patterns of the selected genes were characteristic of lymphomas. We extended the clustering analysis to cell lines from de novo diffuse large B-cell lymphoma (DLBCL). The DLBCL cell lines were either separated from the former 3 lymphoma subtypes or segregated with EBV(+)BL, possibly reflecting variable genetic abnormalities. The associations of CAMK1 with tFL, APP and MADH1 with EBV(-)BL, FGR with EBV(+)BL, and BCL2 with tFL and DLBCL were confirmed by real-time quantitative reverse transcriptase-mediated polymerase chain reaction assays. This study has provided new molecular markers, expressions of which are closely associated with B-cell lymphoma subtypes.
引用
收藏
页码:774 / 781
页数:8
相关论文
共 50 条
  • [1] Comparison of outcomes after allogeneic hematopoietic stem cell transplantation in patients with follicular lymphoma, diffuse large B-cell lymphoma associated with follicular lymphoma, or de novo diffuse large B-cell lymphoma
    Tada, Kohei
    Kim, Sung-Won
    Asakura, Yoshitaka
    Hiramoto, Nobuhiro
    Yakushijin, Kimikazu
    Kurosawa, Saiko
    Tajima, Kinuko
    Mori, Shin-ichiro
    Heike, Yuji
    Tanosaki, Ryuji
    Maeshima, Akiko Miyagi
    Taniguchi, Hirokazu
    Furuta, Koh
    Kagami, Yoshikazu
    Matsuno, Yoshihiro
    Tobinai, Kensei
    Takaue, Yoichi
    Fukuda, Takahiro
    AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (08) : 770 - 775
  • [2] Histologically transformed follicular lymphoma exhibits protein profiles different from both non-transformed follicular and de novo diffuse large B-cell lymphoma
    Ludvigsen, M.
    Madsen, C.
    Kamper, P.
    Hamilton-Dutoit, S. J.
    Bendix, K.
    d'Amore, F.
    Honore, B.
    BLOOD CANCER JOURNAL, 2015, 5 : e293 - e293
  • [3] Histologically transformed follicular lymphoma exhibits protein profiles different from both non-transformed follicular and de novo diffuse large B-cell lymphoma
    M Ludvigsen
    C Madsen
    P Kamper
    S J Hamilton-Dutoit
    K Bendix
    F d'Amore
    B Honoré
    Blood Cancer Journal, 2015, 5 : e293 - e293
  • [4] PD-1 Expression Is Upregulated in Diffuse Large B-Cell Lymphoma Transformed from Marginal Zone Lymphoma and Significantly Higher in Comparison with de novo Diffuse Large B-Cell Lymphoma
    Zhang, Shanxiang
    LABORATORY INVESTIGATION, 2019, 99
  • [5] PD-1 Expression Is Upregulated in Diffuse Large B-Cell Lymphoma Transformed from Marginal Zone Lymphoma and Significantly Higher in Comparison with de novo Diffuse Large B-Cell Lymphoma
    Zhang, Shanxiang
    MODERN PATHOLOGY, 2019, 32
  • [6] Unclassifiable B-cell lymphoma: Between diffuse large B-cell lymphoma and Burkitt lymphoma
    Mandi, Y.
    Malihy, A.
    Kettani, F.
    Alaammari, I.
    Khmou, M.
    Touri, S.
    Rouas, L.
    Lamalmi, N.
    El Khorassani, M.
    Alhamany, Z.
    ARCHIVES DE PEDIATRIE, 2015, 22 (06): : 661 - 664
  • [7] Distinguishing Burkitt lymphoma from diffuse large B-cell lymphoma
    Jack, A.
    ANNALS OF ONCOLOGY, 2011, 22 : 61 - 63
  • [8] B-cell lymphoma, unclassifiable, intermediate between diffuse large B-cell lymphoma and Burkitt's lymphoma
    Baryakh, E. A.
    Misyurina, A. E.
    Kovrigina, A. M.
    Misyurin, V. A.
    Kravchenko, S. K.
    TERAPEVTICHESKII ARKHIV, 2015, 87 (04) : 91 - 97
  • [9] Rituximab maintenance improves outcomes of transformed diffuse large B-cell lymphoma: a retrospective study of 519 cases with de novo diffuse large B-cell lymphoma and 62 cases with concurrent diffuse large B-cell lymphoma and follicular lymphoma
    Uryu, Hideki
    Mishima, Yuko
    Tsuyama, Naoko
    Yokoyama, Masahiro
    Nishimura, Noriko
    Fukuta, Takanori
    Shirouchi, Yuko
    Okabe, Takashi
    Inoue, Norihito
    Takeuchi, Kengo
    Terui, Yasuhito
    LEUKEMIA & LYMPHOMA, 2021, 62 (09) : 2141 - 2150
  • [10] Burkitt lymphoma versus diffuse large B-cell lymphoma
    Rosenwald, A.
    Ott, G.
    ANNALS OF ONCOLOGY, 2008, 19 : 67 - 69